Kervadec et al. 2026: Thirty Years of Ibogaine Research—Narrative Review Takeaways

Definition box

Definition: Kervadec et al. (2026) in the *Journal of Clinical Psychopharmacology* (doi: 10.1097/jcp.0000000000002197) is a narrative review of human clinical literature on ibogaine/noribogaine from 1990 through February 2025. Authors include 24 studies and 38 case reports/series, conclude that current evidence is insufficient to support clinical use, note that no double-blind RCT has demonstrated efficacy for opioid use disorder (OUD), highlight high risk of bias in many positive observational reports, and emphasize cardiotoxicity from QT prolongation as a considerable risk given unproven efficacy. This synthesis is not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Most underlying clinical literature remains oral/observational. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (56 words)

Kervadec and colleagues’ 2026 Journal of Clinical Psychopharmacology narrative review of thirty years of human ibogaine research found insufficient evidence for clinical use, no double-blind RCT proving OUD efficacy, and serious QT-related cardiotoxicity risk. It does not validate psychoactive IV ibogaine infusion. Cardiac screening remains essential. Not FDA-approved.

Why this paper-spoke exists

“Thirty years of research” is a phrase marketers weaponize. Kervadec’s actual conclusion is closer to investigational high-risk compound with inadequate controlled evidence. This spoke keeps that sentence intact. Companions: /blog/kock-2022-ibogaine-systematic-review, /blog/mosca-2023-ibogaine-sud-review, /blog/ibogaine-cure-rate-claims.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Kervadec E., Bezo A., Serreau R., Strika-Bruneau L., Fauvel B., Amirouche A., Benyamina A., Romeo B. *J Clin Psychopharmacol*. 2026;46(4):440–450. doi 10.1097/jcp.0000000000002197 | | Type | Narrative review of human clinical use | | Window | Publications ~1990–February 2025 | | Included | 24 studies + 38 case reports/series | | Focus | Outcomes and safety across indications | | Key conclusion | Evidence insufficient to support clinical use |

Methods (plain language)

Authors searched and synthesized RCTs, open-label, retrospective, and observational reports on ibogaine’s clinical use, summarizing efficacy claims and safety signals. A narrative review can organize three decades of heterogeneous literature without converting weak designs into a regulatory-grade efficacy dossier.

Key findings (no hype)

Author-facing themes:

• Most positive efficacy data come from uncontrolled, open-label, or retrospective studies—often in nonclinical settings—with high risk of bias.
• No double-blind RCT to date has demonstrated that ibogaine or noribogaine effectively treats OUD.
• Only one small RCT reported significant effects for cocaine use disorder (as framed by the review).
• Observational signals for OUD, PTSD, or polysubstance dependence remain exploratory.
• Serious adverse events are reported, especially cardiotoxicity due to QT prolongation, representing considerable risk given currently unproven efficacy.
• Authors position ibogaine as a compound of research interest that still needs better efficacy demonstration and safety optimization before psychiatric-care integration claims.

Honest reading: longevity of interest ≠ adequacy of evidence.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Narrative (not always PRISMA-pooled) | Different from a formal systematic MA | | Heterogeneous doses/settings | Hard to compare apples to apples | | Publication bias | Miracles publish; quiet failures less often | | Case reports inflate extremes | Both “cures” and “catastrophes” | | Route often oral/unspecified | Cannot invent IV RCTs | | Review ≠ new trial | Cannot create missing DB RCT for OUD |

Route honesty: oral ≠ psychoactive IV

Kervadec maps a literature base that does not establish controlled psychoactive-IV efficacy. Brand IV ibogaine infusion must still be described as physician-supervised intravenous psychoactive delivery with sparse controlled IV evidence relative to oral observational series. MISTIC-type protocols remain oral ibogaine + IV magnesium support (/blog/stanford-ibogaine-mistic, /blog/ibogaine-oral-vs-iv).

Cardiac / YMYL context

The review’s QT/cardiotoxicity emphasis aligns with:

• Knuijver 2021/2024 oral QTc + PK/PD (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/knuijver-2024-ibogaine-pk-cyp2d6)
• Ona AE review (/blog/ona-2022-ibogaine-adverse-events-review)
• Brunt CV complications teaching (/blog/ibogaine-cardiovascular-complications-review)
• Mortality spoke (/blog/ibogaine-mortality-cardiac-risk)

Unproven efficacy + documented cardiac risk is exactly why soft CTAs go screening first.

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “30 years proves it works” | False — authors say evidence insufficient for clinical use | | “No OUD DB RCT = ignore cardiac risk” | False — risk still real | | “Narrative review = FDA approval” | False | | Cite as cautious field synthesis? | Yes |

U.S. Schedule I / not FDA (/blog/is-ibogaine-legal-us).

How to read “exploratory PTSD/OUD signals” without cure ads

Observational symptom drops can be meaningful hypotheses and still fail under blinding, expectancy control, and long-term hard outcomes. Families should ask clinics:

1. Which controlled evidence are you citing—and for which route?
2. How do you handle QTc, electrolytes, telemetry, and rescue?
3. What aftercare exists when the “ceremony high” fades? (/blog/ibogaine-aftercare-integration)
4. Are success anecdotes labeled as anecdotes?

Relationship to other paper-spokes

| Paper | Relation | |-------|----------| | Köck 2022 / Mosca 2023 | Earlier systematic maps; Kervadec extends window to early 2025 | | Glue / Knuijver | Controlled-ish safety/PK pieces inside the 30-year arc | | Davis 2020 veterans survey | Exploratory sequential oral program—not DB RCT | | 2025 trial-landscape paper | Shows early-phase trials still dominate (/blog/not-losing-momentum-ibogaine-trials-2025) |

Soft CTA

If “insufficient evidence for clinical use” conflicts with aggressive clinic ads, treat that conflict as a safety signal. Learn cardiac screening at /safety-and-screening, then /apply only after informed questions. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Kervadec 2026 paper? A narrative review of ~30 years of human ibogaine/noribogaine clinical literature concluding evidence is insufficient for clinical use.

Did they find a double-blind RCT proving OUD efficacy? No. Authors state no such DB RCT has demonstrated OUD efficacy.

How many studies were included? Twenty-four studies plus 38 case reports/series (as reported).

Does this prove IV ibogaine infusion works? No. It synthesizes mostly non-IV, non-pivotal evidence and warns about cardiotoxicity.

Why mention QT prolongation? Serious cardiac AEs, especially QT-related cardiotoxicity, are central given unproven efficacy.

Is observational PTSD benefit “proof”? No—review frames such signals as exploratory.

Is ibogaine FDA-approved? No. Schedule I in the U.S.

Where should families start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Kervadec 2026 is a cautious narrative synthesis—not psychoactive IV ibogaine proof and not a cure claim.

Sources (selected)

1. Kervadec E., Bezo A., Serreau R., et al. Thirty Years of Ibogaine Research. *J Clin Psychopharmacol*. 2026;46(4):440–450. doi: 10.1097/jcp.0000000000002197.
2. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
3. Mosca A. et al. *Curr Neuropharmacol*. 2023. doi: 10.2174/1570159X21666221017085612.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).